PMID: 8980748Jan 1, 1997Paper

Therapeutic efficacy of liposomal clofazimine against Mycobacterium avium complex in mice depends on size of initial inoculum and duration of infection

Antimicrobial Agents and Chemotherapy
R KansalR T Mehta

Abstract

The therapeutic efficacy of liposomal clofazimine (L-CLF) against Mycobacterium avium complex (MAC) was evaluated in the acute and chronic infection models of the beige mouse (C57BL/6J bgj bgj). The maximum tolerated dose of L-CLF was inversely proportional to the infection level. L-CLF showed higher antibacterial activity than free clofazimine. Treatment with 25 mg of L-CLF per kg of body weight (intravenously) was started at days 1, 8, 15, and 22 postinfection and was studied at three levels of MAC infection (10(4), 10(5), and 10(6) bacilli/mouse). L-CLF treatment caused a significant (P < 0.05 to 0.001) reduction in the numbers of viable bacteria in lung, liver, and spleen at all infection levels, irrespective of time of treatment. However, the best results were obtained when an already established infection was treated (day 22). The organ-related differences in response to the treatment were also affected by the level of infection. A marked reduction in the numbers of CFU was observed in the lungs of mice with lower infection levels, whereas liver and spleen were treated more efficiently at higher infection levels. These studies might help in evaluations of host responses to therapy.

References

Jun 1, 1978·Antimicrobial Agents and Chemotherapy·P F Bonventre, G Gregoriandis
Jun 1, 1991·The Journal of Infectious Diseases·J J EllnerD M Parenti
Jun 1, 1990·Antimicrobial Agents and Chemotherapy·S P KlemensR S Ginsberg
Aug 1, 1989·Antimicrobial Agents and Chemotherapy·M H CynamonR S Ginsberg
Jan 1, 1989·The American Review of Respiratory Disease·C R Horsburgh, R M Selik
May 1, 1988·The Journal of Infectious Diseases·L S Young
Jan 1, 1988·Critical Reviews in Microbiology·C E SwensonR S Ginsberg
Nov 1, 1986·Reviews of Infectious Diseases·L S YoungM S Gottlieb
May 1, 1986·Antimicrobial Agents and Chemotherapy·V AusinaG Prats
Feb 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G Lopez-BeresteinK Mehta
Jan 1, 1983·Pharmacology & Therapeutics·C R Alving
May 14, 1982·Journal of Chromatography·J H PetersG R Gordon
Aug 1, 1995·Antimicrobial Agents and Chemotherapy·P R Gangadharam
Aug 1, 1995·Clinical and Experimental Immunology·R AppelbergA G Castro
Mar 1, 1994·Research in Microbiology·B Dautzenberg
Apr 1, 1994·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C A Benson
Jun 1, 1993·The Journal of Infectious Diseases·D I AbramsM M Mass

❮ Previous
Next ❯

Citations

Mar 5, 1999·International Journal of Dermatology·T T FajardoG P Walsh
Aug 22, 2000·Antimicrobial Agents and Chemotherapy·M M GasparM E Cruz
Jul 2, 1999·Antimicrobial Agents and Chemotherapy·L B AdamsR T Mehta
Jul 25, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Mpelegeng Victoria BvumbiAndile Ngwane

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.